Literature DB >> 35274283

Assessment of circulating fibrotic proteins (periostin and tenascin -C) In Type 2 diabetes mellitus patients with and without retinopathy.

A Indumathi1, Gandhipuram Periyaswamy Senthilkumar2, Kuppuswamy Jayashree1, K Ramesh Babu3.   

Abstract

PURPOSE: Diabetic retinopathy is a leading cause of vision impairment. Surging diabetic population and poor visual care raises the need for better diagnostic tools. Hence, it is worthwhile to look for biomarkers associated with the disease pathogenesis. Periostin and tenascin-C are matricellular proteins mediating fibrillogenesis in retinopathy. Their serum levels and association with the presence and severity of retinopathy in diabetics is of importance to be explored.
METHODS: The study involved two groups of type 2 diabetes patients, 38 controls without retinopathy and 38 cases with retinopathy. We obtained serum sample and performed biochemical autoanalysis for routine parameters. Special parameters periostin, tenascin-C, and C-peptide were estimated by ELISA.
RESULTS: Periostin and tenascin-C were significantly elevated in the retinopathy group. Periostin progressively increased among subgroups. C-peptide decreased significantly in retinopathy group and had a negative correlation with duration of DM, duration of retinopathy, HbA1c and tenascin-C. We observed a positive correlation for periostin and tenascin-C with duration of diabetes. The AUC for C-peptide was the highest (0.750) amongst our parameters. HOMA 2 (%B) index was significantly lower in retinopathy group.
CONCLUSIONS: Serum Levels of PO and TnC increased in retinopathy. As the disease advances, periostin level increases, indicating continuing fibrosis and fibrovascular membrane formation. Periostin and tenascin-C increase with duration of retinopathy whereas levels of C-peptide decrease. C-peptide has a better differentiating potential for DR from DM. Reduced insulin production as indicated by declined HOMA 2-%BETA in retinopathy favors hyperglycemia and chronic inflammatory state for the disease progression.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  C- peptide; Diabetic retinopathy; Fibrovascular membranes; Periostin; Tenascin-C

Mesh:

Substances:

Year:  2022        PMID: 35274283     DOI: 10.1007/s12020-022-03027-6

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.925


  32 in total

1.  Management of diabetic retinopathy.

Authors:  D Ellis; P I Burgess; P Kayange
Journal:  Malawi Med J       Date:  2013-12       Impact factor: 0.875

Review 2.  Fibrosis and diseases of the eye.

Authors:  Martin Friedlander
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

Review 3.  Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales.

Authors:  C P Wilkinson; Frederick L Ferris; Ronald E Klein; Paul P Lee; Carl David Agardh; Matthew Davis; Diana Dills; Anselm Kampik; R Pararajasegaram; Juan T Verdaguer
Journal:  Ophthalmology       Date:  2003-09       Impact factor: 12.079

4.  Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis.

Authors:  Payal K Naik; Paul D Bozyk; J Kelley Bentley; Antonia P Popova; Carolyn M Birch; Carol A Wilke; Christopher D Fry; Eric S White; Thomas H Sisson; Nabihah Tayob; Barbara Carnemolla; Paola Orecchia; Kevin R Flaherty; Marc B Hershenson; Susan Murray; Fernando J Martinez; Bethany B Moore
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-10-05       Impact factor: 5.464

Review 5.  Overview of epidemiologic studies of diabetic retinopathy.

Authors:  Barbara Eden Kobrin Klein
Journal:  Ophthalmic Epidemiol       Date:  2007 Jul-Aug       Impact factor: 1.648

6.  Characteristics of bone marrow-derived microglia in the normal and injured retina.

Authors:  Hiroki Kaneko; Koji M Nishiguchi; Makoto Nakamura; Shu Kachi; Hiroko Terasaki
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-05-16       Impact factor: 4.799

7.  Periostin promotes liver steatosis and hypertriglyceridemia through downregulation of PPARα.

Authors:  Yan Lu; Xing Liu; Yang Jiao; Xuelian Xiong; E Wang; Xiaolin Wang; Zhijian Zhang; Huijie Zhang; Lingling Pan; Youfei Guan; Dongsheng Cai; Guang Ning; Xiaoying Li
Journal:  J Clin Invest       Date:  2014-07-08       Impact factor: 14.808

Review 8.  Retinal fibrosis in diabetic retinopathy.

Authors:  Sayon Roy; Shruti Amin; Sumon Roy
Journal:  Exp Eye Res       Date:  2016-01       Impact factor: 3.467

9.  The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy.

Authors:  Esther J Kuiper; Frans A Van Nieuwenhoven; Marc D de Smet; Jan C van Meurs; Michael W Tanck; Noelynn Oliver; Ingeborg Klaassen; Cornelis J F Van Noorden; Roel Goldschmeding; Reinier O Schlingemann
Journal:  PLoS One       Date:  2008-07-16       Impact factor: 3.240

Review 10.  The role of periostin in tissue remodeling across health and disease.

Authors:  Simon J Conway; Kenji Izuhara; Yasusei Kudo; Judith Litvin; Roger Markwald; Gaoliang Ouyang; Joseph R Arron; Cecile T J Holweg; Akira Kudo
Journal:  Cell Mol Life Sci       Date:  2013-10-22       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.